Midatech Pharma Plc | CIK:0001643918 | 3

  • Filed: 4/24/2018
  • Entity registrant name: Midatech Pharma Plc (CIK: 0001643918)
  • Generator: Novaworks Software
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1643918/000121465918002960/0001214659-18-002960-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1643918/000121465918002960/mtph-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001643918
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory

    Share-based payments 

    The Group operates a number of equity-settled, share-based compensation plans, under which the entity receives services from employees as consideration for equity instruments (options) of the Group. The fair value of the employee services received in exchange for the grant of the options is recognised as an expense. The total amount to be expensed is determined by reference to the fair value of the options granted: 

      · including any market performance conditions (including the share price);

      · excluding the impact of any service and non-market performance vesting conditions (for example, remaining an employee of the entity over a specified time period); and

      · including the impact of any non-vesting conditions (for example, the requirement for employees to save).

    Non-market performance and service conditions are included in assumptions about the number of options that are expected to vest. The total expense is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. Where vesting conditions are accelerated on the occurrence of a specified event, such as a change in control or initial public offering, such remaining unvested charge is accelerated to the income statement. 

    In addition, in some circumstances employees may provide services in advance of the grant date and therefore the grant date fair value is estimated for the purposes of recognising the expense during the period between service commencement period and grant date. 

    At the end of each reporting period, the Group revises its estimates of the number of options that are expected to vest based on the non-market vesting conditions. It recognises the impact of the revision to original estimates, if any, in the income statement, with a corresponding adjustment to equity. When the options are exercised, the Company issues new shares. The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium.